Cargando…

LRP1 is required for novobiocin-mediated fibronectin turnover

Fibronectin (FN) plays a major role in the stability and organization of the extracellular matrix (ECM). We have previously demonstrated that FN interacts directly with Hsp90, as well as showing that the Hsp90 inhibitor novobiocin results in FN turnover via a receptor mediated process. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Boel, Natasha Marie-Eraine, Hunter, Morgan Campbell, Edkins, Adrienne Lesley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065439/
https://www.ncbi.nlm.nih.gov/pubmed/30061663
http://dx.doi.org/10.1038/s41598-018-29531-2
_version_ 1783342869142044672
author Boel, Natasha Marie-Eraine
Hunter, Morgan Campbell
Edkins, Adrienne Lesley
author_facet Boel, Natasha Marie-Eraine
Hunter, Morgan Campbell
Edkins, Adrienne Lesley
author_sort Boel, Natasha Marie-Eraine
collection PubMed
description Fibronectin (FN) plays a major role in the stability and organization of the extracellular matrix (ECM). We have previously demonstrated that FN interacts directly with Hsp90, as well as showing that the Hsp90 inhibitor novobiocin results in FN turnover via a receptor mediated process. However, the receptor involved has not been previously identified. LRP1 is a ubiquitous receptor responsible for the internalisation of numerous ligands that binds both Hsp90 and FN, and therefore we investigated whether LRP1 was involved in novobiocin-mediated FN turnover. FN, LRP1 and Hsp90 could be isolated in a common complex, and inhibition of Hsp90 by novobiocin increased the colocalisation of FN and LRP1. Novobiocin induced an increase (at low concentrations) followed by a loss of FN that was primarily derived from extracellular matrix-associated FN and led to a concomitant increase in intracellular FN. The effect of novobiocin was specific to LRP1-expressing cells and could be recapitulated by an LRP1 blocking antibody and the allosteric C-terminal Hsp90 inhibitor SM253, but not the N-terminal inhibitor geldanamycin. Together these data suggest that LRP1 is required for FN turnover in response to Hsp90 inhibition by novobiocin, which may have unintended physiological consequences in contexts where C-terminal Hsp90 inhibition is to be used therapeutically.
format Online
Article
Text
id pubmed-6065439
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-60654392018-08-06 LRP1 is required for novobiocin-mediated fibronectin turnover Boel, Natasha Marie-Eraine Hunter, Morgan Campbell Edkins, Adrienne Lesley Sci Rep Article Fibronectin (FN) plays a major role in the stability and organization of the extracellular matrix (ECM). We have previously demonstrated that FN interacts directly with Hsp90, as well as showing that the Hsp90 inhibitor novobiocin results in FN turnover via a receptor mediated process. However, the receptor involved has not been previously identified. LRP1 is a ubiquitous receptor responsible for the internalisation of numerous ligands that binds both Hsp90 and FN, and therefore we investigated whether LRP1 was involved in novobiocin-mediated FN turnover. FN, LRP1 and Hsp90 could be isolated in a common complex, and inhibition of Hsp90 by novobiocin increased the colocalisation of FN and LRP1. Novobiocin induced an increase (at low concentrations) followed by a loss of FN that was primarily derived from extracellular matrix-associated FN and led to a concomitant increase in intracellular FN. The effect of novobiocin was specific to LRP1-expressing cells and could be recapitulated by an LRP1 blocking antibody and the allosteric C-terminal Hsp90 inhibitor SM253, but not the N-terminal inhibitor geldanamycin. Together these data suggest that LRP1 is required for FN turnover in response to Hsp90 inhibition by novobiocin, which may have unintended physiological consequences in contexts where C-terminal Hsp90 inhibition is to be used therapeutically. Nature Publishing Group UK 2018-07-30 /pmc/articles/PMC6065439/ /pubmed/30061663 http://dx.doi.org/10.1038/s41598-018-29531-2 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Boel, Natasha Marie-Eraine
Hunter, Morgan Campbell
Edkins, Adrienne Lesley
LRP1 is required for novobiocin-mediated fibronectin turnover
title LRP1 is required for novobiocin-mediated fibronectin turnover
title_full LRP1 is required for novobiocin-mediated fibronectin turnover
title_fullStr LRP1 is required for novobiocin-mediated fibronectin turnover
title_full_unstemmed LRP1 is required for novobiocin-mediated fibronectin turnover
title_short LRP1 is required for novobiocin-mediated fibronectin turnover
title_sort lrp1 is required for novobiocin-mediated fibronectin turnover
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065439/
https://www.ncbi.nlm.nih.gov/pubmed/30061663
http://dx.doi.org/10.1038/s41598-018-29531-2
work_keys_str_mv AT boelnatashamarieeraine lrp1isrequiredfornovobiocinmediatedfibronectinturnover
AT huntermorgancampbell lrp1isrequiredfornovobiocinmediatedfibronectinturnover
AT edkinsadriennelesley lrp1isrequiredfornovobiocinmediatedfibronectinturnover